Nutriband announces a 25% preferred stock dividend for shareholders, payable August 5, 2025, pending FDA approval of AVERSA product.
Quiver AI Summary
Nutriband Inc. has announced a 25% preferred stock dividend for its shareholders, with those on record by July 25, 2025, set to receive one preferred share for every four common shares held. The dividend will be payable on August 5, 2025. These preferred shares can be converted into common stock following FDA approval of Nutriband's AVERSA fentanyl product, which features abuse-deterrent technology aimed at improving safety for transdermal drugs while maintaining access for patients. Nutriband is focused on developing transdermal pharmaceutical products and holds a robust patent portfolio for its technology. The company includes cautionary notes about forward-looking statements regarding its business development and regulatory challenges.
Potential Positives
- Nutriband is distributing a 25% preferred stock dividend, which may enhance shareholder value and demonstrate confidence in the company's future prospects.
- The preferred shares will be convertible into common stock following FDA approval of the AVERSA product, providing potential upside for investors.
- AVERSA™ technology addresses a significant market need for abuse-deterrent medications, positioning Nutriband as a leader in this innovative space.
- The company holds a broad intellectual property portfolio for AVERSA™, strengthening its competitive position and potential for future revenue generation.
Potential Negatives
- The requirement for FDA approval of the AVERSA Fentanyl product before the preferred shares can be converted into common stock may indicate regulatory hurdles that could delay or complicate the product's market entry.
- The reliance on a preferred stock dividend tied to the company's future product success may raise concerns among shareholders about the company's current financial stability and ability to generate immediate profits.
- The press release emphasizes the company's potential risks and uncertainties, which could negatively impact investor confidence and perception of the company's viability and growth prospects.
FAQ
What is Nutriband's preferred stock dividend?
Nutriband is issuing a 25% preferred stock dividend, with shareholders receiving one preferred share for every four common shares held.
When will shareholders receive their preferred shares?
Shareholders of record on July 25th, 2025, will receive their preferred shares on August 5th, 2025.
How does the AVERSA technology work?
The AVERSA technology incorporates aversive agents in transdermal patches to prevent the misuse and abuse of drugs, including fentanyl.
What is the significance of the FDA approval?
Each preferred share can be converted to common stock upon FDA approval of Nutriband's AVERSA fentanyl product.
Where can I find more information about Nutriband?
Additional information about Nutriband can be found on their website at www.nutriband.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NTRB Hedge Fund Activity
We have seen 8 institutional investors add shares of $NTRB stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 74,437 shares (+59.7%) to their portfolio in Q1 2025, for an estimated $456,298
- AVANTAX ADVISORY SERVICES, INC. removed 13,647 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $83,656
- NORTHERN TRUST CORP added 11,482 shares (+inf%) to their portfolio in Q1 2025, for an estimated $70,384
- CONSOLIDATED PORTFOLIO REVIEW CORP added 10,350 shares (+inf%) to their portfolio in Q2 2025, for an estimated $81,454
- CITIGROUP INC added 10,209 shares (+inf%) to their portfolio in Q1 2025, for an estimated $62,581
- US BANCORP \DE\ added 4,798 shares (+inf%) to their portfolio in Q1 2025, for an estimated $29,411
- MORGAN STANLEY added 3,549 shares (+inf%) to their portfolio in Q1 2025, for an estimated $21,755
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NTRB Analyst Ratings
Wall Street analysts have issued reports on $NTRB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Noble Capital Markets issued a "Outperform" rating on 01/22/2025
To track analyst ratings and price targets for $NTRB, check out Quiver Quantitative's $NTRB forecast page.
Full Release
ORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) (“Nutriband” or the “Company”) is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend.
Shareholders of record on July 25 th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August. 5 th .
Each preferred share will be convertible to one share of common stock following FDA approval of the Company’s AVERSA Fentanyl product.
If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an annual basis as decided by the board of Directors.
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com . Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information
:
Nutriband Inc.
Phone: 407-377-6695
Email:
[email protected]
SOURCE:
Nutriband Inc.
